Induction of Cytochrome P450 1A1 in Mice by Repeated Oral Administration of Propranolol

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 1, 2002, Pages 54-59

  Narimatsu, Shizuo ^a   Yamamoto, Shigeo ^b   Mochida, Masayuki ^c   Horie, Toshiharu ^c   Suzuki, Tokuji ^c   Ueno, Koichi ^d  

^a NTT Service Evolution   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c Departments of Biopharmaceutics   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

CYP1A1; CYP1A2; induction; mouse; propranolol; species difference

Indexed keywords

EID: 33751577980     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.54     Document Type: Article

References (29)

1. Evans, G. H. and Shand, D. G.: Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin. Pharmacol. Ther., 14: 487-493 (1973).
2. Straka, R. J., Lalonde, R. L., Pieper, J. A., Bottorff, M. B. and Mirvis, D. M.: Nonlinear pharmacokinetics of unbound propranolol after oral administration. J. Pharm. Sci., 76: 521-524 (1987).
3. Schneck, D. W. and Pritchard, J. F.: The inhibitory effect of propranolol pretreatment on its own metabolism in the rat. J. Pharmacol. Exp. Ther., 218: 575-581 (1981).
4. Masubuchi, Y., Fujita, S., Chiba, M., Kagimoto, N., Umeda, S. and Suzuki, T.: Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol. Biochem. Pharmacol., 41: 861-865 (1991).
5. Narimatsu, S., Mochida, M., Matsumoto, T., Masubuchi, Y., Horie, T., Nagata, K., Funae, Y., Cho, A. K. and Suzuki, T.: Cytochrome P450 enzymes involved in the enhancement of propranolol N-desisopropylation after repeated administration of propranolol in rats. Chemico-Biol. Interact., 101: 207-224 (1996).
6. Narimatsu, S., Watanabe, T., Mochida, M., Masubuchi, Y., Horie, T., Kumagai, Y., Cho, A. K., Imaoka, S., Funae, Y., Ishikawa, T. and Suzuki, T.: Characterization of a chemically reactive propranolol metabolite that bind to microsomal proteins of rat liver. Chem. Res. Toxicol., 8: 721-728 (1995).
7. Narimatsu, S., Arai, T., Watanabe, T., Horie, T., Suzuki, T., Ishikawa, T., Tsutsui, M., Kumagai, Y. and Cho, A. K.: Covalent binding of a reactive metabolite derived from propranolol and its active metabolite 4-hydroxypropranolol to hepatic microsomal proteins in the rat. Chem. Res. Toxicol., 10: 289-295 (1997).
8. Narimatsu, S., Arai, T., Masubuchi, Y., Horie, T., Hosokawa, M., Ueno, K., Kataoka, H., Yamamoto, S., Ishikawa, T. and Cho, A K.: Inactivation of rat cytochrome P450 2D enzyme by a further metabolite of 4-hydroxypropranolol, the major and active metabolite of propranolol. Biol. Pharm. Bull., 24: 988-994 (2001).
9. Y. Masubuchi, N. Kagimoto, S. Narimatsu, S. Fujita and T. Suzuki. Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes. Drug Metab. Dispos., 21, 1012-1016 (1993).
10. Masubuchi, Y., Hosokawa, S., Horie, T., Ohmori, S., Kitada, M., Suzuki, T. and Narimatsu, S.: Cytochrome P-450 isozymes involved in propranolol metabolism in human liver microsomes: The role of CYP-2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab. Dispos., 22: 909-915 (1994).
11. Masubuchi, Y., Iwasa, T., Hosokawa, S., Suzuki, T., Horie, T., Imaoka, S., Funae, Y. and Narimatsu, S.: Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J. Pharamcol. Exp. Ther., 282: 1435-1441 (1997).
12. Gonzalez, F. J., Tukey, R. H. and Nebert, D. W.: Structural gene products of the Ah locus. Transcriptional regulation of cytochrome P1-450 and P3-450 mRNA levels by 3-methylcholanthrene. Mol. Pharmacol., 26: 117-121 (1984).
13. Oatis, J. E., Russell, M. P., Knapp, D. R. and Walle, T.: Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers. J. Med. Chem., 24: 309-314 (1981).
14. Omura, T. and Sato, R.: T. Omura, R. Sato. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem., 239: 2370-2378 (1964).
15. Burke, M. D. Prough, R. A. and Mayer, R. T.: Characteristics of a microsomal cytochrome P-448-mediated reaction. Ethoxyresorufin O-deethylation. Drug Metab. Dispos., 5: 1-8 (1977).
16. Klippert, P. J., Littel, R. J. and Noordhoek, J.: In vivo O-de-ethylation of phenacetin in 3-methylcholanthrene-pretreated rats: gut wall and liver first-pass metabolism. J. Pharmacol. Exp. Ther., 225: 153-157 (1983).
17. Sesardic, D., Edwards, R. J. Davies, D. S., Thomas, P. E., Levin, W. and Boobis A. R.: High affinity phenacetin O-deethylase is catalysed specifically by cytochrome P450d (P450IA2) in the liver of the rat. Biochem. Pharmacol., 39: 489-498 (1990).
18. Fujita, S., Matsunaga, T., Masubuchi, Y. and Suzuki, T.: Possible mechanism of Sudan III-induced prevention of chemical carcinogenesis in rats. Cancer Res., 48: 254-259 (1988).
19. Fujita, S., Morimoto, R., Chiba, M., Kitani, K. and Suzuki, T.: Evaluation of the involvement of a male specific cytochrome P-450 isozyme in senescence-associated decline of hepatic drug metabolism in male rats. Biochem. Pharmacol., 38: 3925-3931 (1989).
20. Suzuki, T., Narimatsu, S., Fujita, S., Masubuchi, Y., Umeda, S., Imaoka, S. and Funae, Y.: Purification and characterization of a cytochrome P-450 isozyme catalyzing bunitrolol 4-hydroxylation in liver microsomes of male rats. Drug Metab. Dispos., 20: 367-373 (1992).
21. Guengerich, F. P., Wang, P. and Davidson, N. K.: Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry, 21: 1698-1706 (1982).
22. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275 (1951).
23. Kimura, S., Smith, H. H., Hankinson, O. and Nebert, D. W.: Analysis of two benzo[a]pyrene-resistant mutants of the mouse hepatoma Hepa-1 P(1)450 gene via cDNA expression in yeast. EMBO J., 6: 1929-1933 (1987).
24. Kimura, S., Gonzalez, F. J. and Nebert, D. W.: Mouse cytochrome P3-450: complete cDNA and amino acid sequence. Nucleic Acids Res., 12: 2917-2928 (1984)
25. Rodrigues, A. D. and Prough, R. A.: Induction of cytochromes P450IA1 and P450IA2 and measurement of catalytic activities. Methods Enzymol., Vol. 206, pp. 423-431, eds. by Waterman, R., Johnson, E. F., Academic Press, San Diego, 1991.
26. Nerurkar, P. V., Park, S. S., Thomas, P. E., Nims, R. W. and Lubet R. A.: Methoxyresorufin and benzylox-yresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse. Biochem. Pharmacol., 46: 933-943 (1993).
27. Lambrecht, R. W., Sinclair, P. R., Gorman, N. and Sinclair, J. F.: Uroporphyrinogen oxidation catalyzed by reconstituted cytochrome P450IA2. Arch. Biochem. Biophys., 294: 504-510 (1992).
28. Whitlock, J. P. Jr.: Induction of cytochrome P4501A1. Ann. Rev. Pharmacolo. Toxicol., 39: 103-125 (1999).
29. Kikuchi, H. and Hossain, A.: Signal transduction-mediated CYP1A1 induction by omeprazole in human HepG2 cells. Exp. Toxicol. Pathol., 51: 342-346 (1999).